Reviva Pharmaceuticals Holdings Inc. (RVPH): Price-to-Sales Ratio

Corporate company logo of Reviva Pharmaceuticals Holdings (RVPH)

Reviva Pharmaceuticals (RVPH) revenues are based on the future commercialization of Brinzolazine, which creates temporary financial risks. The price-to-sales ratio on the GURU.Markets chart, with a metric value of , illustrates market expectations. Venture capital will help overcome the barriers of costly trials and patent restrictions, while the bet on safe Brinlarikazine will ensure active growth for the company.

RVPH: Reviva Pharmaceuticals P/S Multiple 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for revivapharma.com (RVPH)

- share price and consensus valuation forecast:
Price Performance Chart Reviva Pharmaceuticals Holdings Inc.|RVPH - Price Target Chart
- stock exchange capitalization data:
Market Valuation Reviva Pharmaceuticals, Inc.|RVPH - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Reviva Pharmaceuticals|RVPH - Book Capitalization|Market Capitalization to Book Value Ratio revivapharma.com|RVPH - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Reviva Pharmaceuticals|RVPH - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Reviva Pharmaceuticals|RVPH - Company Aggregate Debts|Debts to Book Capitalization Reviva Pharmaceuticals, Inc.|RVPH - Company Long-Term Debts|Company Current Liabilities Reviva Pharmaceuticals|Immediate Liquidity revivapharma.com
- earnings and valuation multiples information:
RVPH - Net Income|Projected Future Earnings Reviva Pharmaceuticals|RVPH - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Reviva Pharmaceuticals Holdings|RVPH - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Reviva Pharmaceuticals, Inc.|RVPH - Operating profit EBITDA|Net earnings per share for the last 12 months Reviva Pharmaceuticals|RVPH - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth revivapharma.com|RVPH - Earnings per share growth in current year|Net earnings per share growth forecast for next year Reviva Pharmaceuticals
- issuer revenue and sales details:
RVPH - Company Revenue|Company Future Sales Reviva Pharmaceuticals Holdings Inc.|RVPH - Price-to-Revenue Ratio|Forward Price to Sales Reviva Pharmaceuticals Holdings, Inc.
General company analysis:RVPH Reviva Pharmaceuticals Holdings, Inc.
Finished products of Reviva Pharmaceuticals

The success of clinical trials for antipsychotic drugs will provide Reviva Pharmaceuticals (RVPH) with a competitive market advantage and premium pricing power. By analyzing the company's P/S chart, an investor assesses the ratio of market capitalization to actual sales volume. This multiple determines how many dollars of business value are attributed to one dollar of revenue, revealing whether the asset is overvalued or undervalued. The stability of this metric confirms the fundamental resilience of the business model within the biopharmaceutical sector.

Competing companies

BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue cogrx.com (CGTX)|Price-to-Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Price-to-Revenue Coefficient Cassava Sciences|P/S Multiple ASRT (Assertio Holdings)|COYA - Market Cap to Revenue|vistagen.com - P/S Multiple|OVID: Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Revenue Ratio|CervoMed Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Price-to-Revenue Coefficient|Market Cap to Revenue PEPG (PepGen Inc)|P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Revenue Ratio|KLTO: P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - P/S Multiple|MTVA (metaviatx.com) - P/S Multiple|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|ATHA: Market Cap to Revenue|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue